A phase II study of tasisulam sodium as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma
Investigational New Drugs, 05/04/2012Ryan CW et al.
Tasisulam at a target Cmax of 420µg/mL on day 1 of 21–day cycles demonstrated modest activity as second–/third–line treatment in patients with soft tissue sarcoma (STS). Grade 4 hematologic toxicity posed some challenges in these heavily pre–treated patients. Tasisulam dosing continues to be refined.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.